Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling

Diabetes, Obesity and Metabolism

Volumn 11, Issue 6, 2009, Pages 579-588

  Erbe, David V ^a   Klaman, L D ^a   Wilson, D P ^a   Wan, Z K ^a   Kirincich, S J ^a   Will, S ^a   Xu, X ^a   Kung, L ^a   Wang, S ^a   Tam, S ^a   Lee, J ^a   Tobin, J F ^a  

^a PFIZER INC   (United States)

Author keywords

Diabetes; Insulin resistance; Leptin; Obesity; Phosphatase

Indexed keywords

DRUG METABOLITE; INSULIN; LEPTIN; PHOSPHOTYROSINE; PRODRUG; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVE SITE; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RAT; SIGNAL TRANSDUCTION; TARGET ORGAN;

EID: 65549091169     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01022.x     Document Type: Article

References (35)

1. Zimmel P, Alberti KM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
2. Flier JS. Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
3. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806.
4. Cheng A, Uetani N, Simoncic PD et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2002; 2: 385-387.
5. Elchebly M, Payette P, Michaliszyn E et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1b gene. Science 1999; 283: 1544-1548.
6. Klaman LD, Boss O, Peroni OD et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1b-deficient mice. Mol Cell Biol 2000; 20: 5479-5489.
7. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-495.
8. Zinker BA, Rondinone CM, Trevillyan JM et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 99: 11357-11362.
9. Gum RJ, Gaede LL, Koterski SL et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003; 52: 21-28.
10. Bhanot S, Butler M, Booten S et al. Effects of a novel PTP1B antisense inhibitor (ISIS 113715) in cynomolgus monkeys. Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies Conference: 27 Jan-2 Feb, Keystone, CO, USA 2002; Abstract 202.
11. Tonks NK. PTP1B: From the sidelines to the frontlines! FEBS Lett 2003; 546: 140-148.
12. Hooft van Huijsduijnen R, Sauer WHB, Bombrun A, Swinnen D. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs. J Med Chem 2004; 47: 4142-4146.
13. Tobin JF, Tam S. Recent advances in the development of small molecule inhibitors of PTP1B for the treatment of insulin resistance and type 2 diabetes. Curr Opin Drug Discov Devel 2002; 5: 500-512.
14. Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 2002; 1: 696-709.
15. Zhang Y-L, Tobin JF, Erbe DV. PTP1B: A promising and challenging target for metabolic disease. Int J Pharm 2006; 2: 93-97.
16. Kasibhatla B, Wos J, Peters KG. Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes. Curr Opin Investig Drugs 2007; 8: 805-813.
17. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, Zhang Z-Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design. Proc Natl Acad Sci U S A 1997; 94: 13420-13425.
18. Wrobel J, Sredy J, Moxham C et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. J Med Chem 1999; 42: 3199-3202.
19. Erbe DV, Wang S, Zhang YL et al. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol 2005; 67: 69-77.
20. Burkey BF, Dong M, Wennogle L et al. Pharmacogenomic evaluation of a putative orally active PTP-1B inhibitor using ob/ob mice reveals an alternative mechanism of action. 62nd American Diabetes Association Annual Meeting: 14-18 June, San Francisco, CA, USA 2002; Abstract 138.
21. Moretto AF, Kirincich SJ, Xu WX et al. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1b inhibitors. Bioorg Med Chem 2006; 14: 2162-2177.
22. Wilson DP, Wan Z-K, Xu W-X et al. Structure-based optimization of protein tyrosine phosphatase 1b inhibitors: From the active site to the second phosphotyrosine binding site. J Med Chem 2007; 50: 4681-4698.
23. Wan ZK, Lee J, Xu W et al. Monocyclic thiophenes as protein tyrosine phosphatase 1b inhibitors: Capturing interactions with Asp48. Bioorg Med Chem Lett 2006; 16: 4941-4945.
24. Zhang Y-L, Tam M, Kirincich S et al. An enzyme-linked immunosorbent assay to measure insulin receptor dephosphorylation by PTP1B. Anal Biochem 2007; 365: 174-184.
25. Aoki N, Matsuda T. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 2000; 275: 39718-39726.
26. Erbe DV, Gartrell K, Zhang YL et al. Molecular activation of PPARγ by angiotensin II type-1 receptor antagonists. Vascul Pharmacol 2006; 45: 154-162.
27. Silva ATDA, Chung MC, Castro LF, Guido RVC, Ferreira EI. Advances in prodrug design. Mini Rev Med Chem 2005; 5: 893-914.
28. Gomez-Orellana I. Strategies to improve oral bioavailability. Expert Opin Drug Deliv 2005; 2: 419-433.
29. Di L, Kerns EH. Application of pharmaceutical profiling assays for optimization of drug-like properties. Curr Opin Drug Discov Devel 2005; 8: 495-504.
30. Redinbo MR, Potter PM. Mammalian carboxylesterases: From drug targets to protein therapeutics. Drug Discov Today 2005; 10: 313-325.
31. Han H-K, Amidon GL. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000; 2: 1-11.
32. Wiesmann C, Barr KJ, Kung J et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 2004; 11: 730-737.
33. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008; 31: 1-11.
34. Koivisto U-M, Martinez-Valdez H, Bilan PJ, Burdett E, Ramlal T, Klip A. Differential regulation of the GLUT-1 and GLUT-4 glucose transport systems by glucose and insulin in L6 muscle cells in culture. J Biol Chem 1991; 266: 2615-2621.
35. Bleasdale JE, Ogg D, Palazuk BJ et al. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry 2001; 40: 5642-5654.